Artificial intelligence news.
Straight from the original announcements.

DxCheck Launches DxPro, a Free AI Workspace for Verified U.S. Clinicians

October 29, 2026, 13:13Source: PR Newswire
DxCheck Launches DxPro, a Free AI Workspace for Verified U.S. Clinicians
Image: PR Newswire

DxCheck has launched DxPro, an AI-powered workspace for practicing U.S. healthcare professionals that combines cited clinical answers, daily specialty updates and patient experience insights. According to the company, access is free for verified clinicians and the platform is available now.

Key points
  • DxCheck launched DxPro, an AI-powered workspace for practicing U.S. healthcare professionals.
  • The Lens feature gives AI answers to clinical questions, each citing its sources.
  • Other tools include a specialty Clinical Intelligence Feed, Treatment Landscape Alerts and Patient Voice Reports.
  • Access requires NPI verification and is free for verified clinicians.
  • DxPro is available now at pro.dxcheck.com.

What DxPro offers

DxCheck, a health information platform for patients and caregivers, says DxPro is tailored to each clinician's specialty. The goal, according to the company, is to narrow a constant stream of approvals, label changes, trial readouts and safety communications down to what matters in a given field. Clinicians typically have to follow that flow in the margins of a full patient schedule.

Chris Searles, CEO and Co-Founder of DxCheck, framed the product around time pressure. "Physicians have never had more to keep up with, or less time to do it," he said. He added that DxPro "does the sorting for them" so that they spend less time searching and more time with patients.

The tools inside the workspace

Once a clinician has been verified through their NPI, DxCheck says they can access several features:

  • Lens: AI-powered answers to clinical questions, each citing its sources.
  • Clinical Intelligence Feed: safety alerts, FDA approvals, new trials, guideline updates, major new studies and public health reports, gathered for each specialty.
  • Treatment Landscape Alerts: FDA approvals, new indications, safety communications and recalls.
  • Patient Voice Reports: on-demand summaries of what patients and caregivers say about conditions and treatments in the clinician's specialty, drawn from popular patient review sites and forums.

The platform also includes Conference Summaries, Case Studies and Clinical Trial Matching, which is designed for recruiting trials near any ZIP code.

Connecting clinicians and patient content

DxPro also lets clinicians review DxCheck's patient content in their specialty. DxCheck says this is meant to help keep patient information accurate. The company describes the broader idea as having patients and clinicians on one platform, so that both "arrive at the same conversation better prepared."

DxCheck describes itself as a next-generation health information platform founded by a team of digital health veterans. Its existing service guides patients and caregivers through their medical journey with personalized content backed by verified clinical sources.

Availability and what it means

DxPro is available now at pro.dxcheck.com, and access is free for verified clinicians. The launch extends DxCheck from a patient-facing service to a tool for the professionals who treat those patients. For clinicians, the pitch is a single place for sourced answers and specialty-specific monitoring. The source does not provide usage figures or performance data, so how well the tools work in practice remains to be seen.

Related news

Research
ResearchNovember 3, 2026, 11:48

Differentia Bio's AI models matched later clinical outcomes

Differentia Bio says its disease-modeling platform identified therapeutic mechanisms between 2023 and 2024 that were later supported by independent clinical results. One…

Vanda's NEREUS Cuts Semaglutide-Induced Vomiting in Phase III Trial
ResearchOctober 27, 2026, 11:50

Vanda's NEREUS Cuts Semaglutide-Induced Vomiting in Phase III Trial

Vanda Pharmaceuticals says its oral drug NEREUS (tradipitant) significantly reduced vomiting caused by semaglutide in the Phase III Study 3601. The company plans to…

Products and tools
Products and toolsOctober 23, 2026, 21:33

FDA Approves Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease

The U.S. Food and Drug Administration has approved a subcutaneous induction regimen for AbbVie's Skyrizi (risankizumab-rzaa) in adults with moderately to severely active…